Optimedia has won the £60 million global media planning and
buying account for the drug company Sanofi-Synthelabo.
The appointment follows a global review involving five networks that
went down to a shortlist of two. The agency beat the incumbent, OMD, in
a final pitch.
Optimedia will work for Sanofi in 35 countries, including the UK, with
Optimedia Paris acting as lead agency. Its task is to work on media
planning and buying for Sanofi's business-to-business, over-the-counter,
corporate and financial communications. It will begin working on the
account from January 2002.
Sanofi produces a variety of drugs, including treatments for
cardiovascular and central nervous system conditions. It is the
seventh-largest pharmaceutical group in Europe and is looking to expand
into the US and Asia. Its largest European market is France.
Simon Lloyd, Optimedia's chairman, said: "Sanofi has a presence in more
than 100 countries and was looking for a partner with a strong
international communications network. We are delighted to have been
appointed to work with one of the world's foremost pharmaceutical
groups; it is a great endorsement."
Separately, Optimedia has been awarded the global media account for
AspenTech, a provider of software solutions to industry.